Physician profile
Deena Tailor
NPI 1104356815
$4,959.81
in general payments reported to CMS, 2019-2025
23 companies · $509 in 2025
The $509 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $258 · 2021: $840 · 2022: $700 · 2023: $1,038 · 2024: $1,140 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,030.43 | 2022-2024 | Lumigan, Vuity, Alphagan P |
| Sun Pharmaceutical Industries INC. | $902.48 | 2019-2025 | Cequa |
| Alcon Vision LLC | $481.38 | 2021-2025 | Dailies Total1, Precision 1, Total30 |
| Kala Pharmaceuticals, INC. | $402.62 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $245.75 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $236.83 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $214.85 | 2024-2025 | Xdemvy |
| Allergan, INC. | $186.70 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $186.28 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $171.07 | 2019-2021 | |
| Oyster Point Pharma, INC. | $142.12 | 2022-2024 | Tyrvaya |
| Shire North American Group INC | $121.66 | 2019 | |
| Sight Sciences, INC. | $111.75 | 2024 | Omni Surgical System |
| Coopervision INC. | $103.99 | 2024 | Misight Contact Lens |
| Aerie Pharmaceuticals, INC. | $85.86 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $82.41 | 2022 | |
| Rxsight INC | $78.39 | 2022 | |
| Carl Zeiss Meditec, INC. | $43.65 | 2019 | |
| Glaukos Corporation | $37.50 | 2025 | Idosetr |
| Mallinckrodt Hospital Products INC. | $33.92 | 2022 | |
| Dompe US, INC. | $30.35 | 2024 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $15.58 | 2023 | Acuvue |
| Harrow Eye, LLC | $14.24 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deena Tailor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.